Company
Cartiva
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
3
510(k), De Novo and PMA
Device trials
5
As lead sponsor, any status
Adverse event reports
59
Received Nov 1, 2025 to Nov 20, 2026
Recall records
1
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.
Total raised (reported)
$18.8M
4 Form D offerings, 2013 to 2016
Equity
$18.8M
Stock sold for cash
Debt and convertible notes
$0
Loans and notes sold to investors
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: equity, $7.0M raised of $8.5M sought, first sale Nov 9, 2016, 2 investors.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Nov 9, 2016 | Equity | $7.0M | $8.5M | 2 | Rule 506(b) | Form D ↗Nov 18, 2016 |
3 more funding rounds with a free account
Company details
From the company's latest Form D.
- Legal name
- Cartiva, Inc.
- Headquarters
- Alpharetta, Georgia
- Incorporated
- Delaware in 2011
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Other Health Care
- SEC filer
- CIK 1539128 ↗
Executives, directors and promoters
As listed on the latest Form D.
11 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Cartiva.
Latest FDA decisions
K192156 · Decided Sep 4, 2019 · 26 days after receipt
Device type: Instruments Designed For Press-Fit Osteochondral Implants (QBO) · Orthopedic Surgery
2 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Safety and Effectiveness of Cartiva Implant in the Treatment of First CMC Joint Osteoarthritis Compared to LRTI (GRIP 2)Status unknown
NCT03247439 · 74 participants · Start Dec 22, 2017 · Primary completion Oct 30, 2020
Device: Cartiva · For: Osteoarthritis
Sites: San Diego, California; Atlanta, Georgia; Indianapolis, Indiana · 9 sites in all
4 more trials with a free account
Reports received
59
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
0.0% of reports
Injury reports
59
100% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 1 | 0 | 0 |
| Jan 24 | 0 | 1 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 2 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 126 | 0 | 0 |
| Nov 24 | 0 | 1 | 0 | 0 |
| Dec 24 | 0 | 36 | 0 | 0 |
| Jan 25 | 0 | 143 | 0 | 0 |
| Feb 25 | 0 | 3 | 0 | 0 |
| Mar 25 | 0 | 9 | 0 | 0 |
| Apr 25 | 0 | 1 | 0 | 0 |
| May 25 | 0 | 11 | 0 | 0 |
| Jun 25 | 0 | 34 | 0 | 0 |
| Jul 25 | 0 | 4 | 0 | 0 |
| Aug 25 | 0 | 2 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 22 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 3 | 0 | 0 |
| Jan 26 | 0 | 3 | 0 | 0 |
| Feb 26 | 0 | 5 | 0 | 0 |
| Mar 26 | 0 | 1 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 1 | 0 | 0 |
| Jun 26 | 0 | 4 | 0 | 0 |
| Jul 26 | 0 | 1 | 0 | 0 |
| Aug 26 | 0 | 30 | 0 | 0 |
| Sep 26 | 0 | 11 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
The full in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
4 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Cartiva Synthetic Cartilage Implant (SCI) Catalog: CAR-06-US (6mm), CAR-08-US (8mm), CAR-10-US (10mm), CAR-12-US (12mm)Open, Classified
Z-0598-2025 · Started Oct 31, 2024 · Posted by FDA Dec 4, 2024
Reason given: Patients implanted with synthetic cartilage implant, may experience a higher-than expected occurrence rate of the following hazards: revision, removal, implant subsidence, displacement, pain, nerve damage or fragmentation.
Cause as FDA categorized it: Device Design · Device type: Prosthesis, Metatarsophalangeal Joint Cartilage Replacement Implant (PNW)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.